Preliminary study of central nervous system tumors’ prevalence and incidence in Isfahan Province Iran

Tolou-Ghamari, Zahra

doi:10.1186/s43046-020-00022-8

Cited by 5 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(10) Another study in Isfahan Province, Iran, showed that the prevalence of brain and other nervous system tumors was 1.4 times higher in males than in females, with a 35.7% increase in the incidence rate over the study period. (11) Past studies have produced diverse and at times inconclusive results due to regional variations and different methodologies. Compared to these studies, this study was conducted at one of the largest cancer centers in Tehran, the capital city of Iran, which is a referral center for many patients from different regions.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of primary central nervous system tumors in Iran: a retrospective study

Amini Harandi,

Zarifi,

Shahmohammadi

2023

Univ Med

View full text Add to dashboard Cite

BackgroundTumors are the second-most common cause of death after cardiovascular diseases. Brain tumors are really different regarding location, symptoms and signs. The aim of this study was to determine the prevalence of different primary brain tumors in Iran. MethodsThis cross-sectional study analyzed the medical records of patients with primary brain tumor referred to university hospitals between January 2016 and January 2017. By examining the hospitalization records, clinical symptoms, pathological and imaging findings, data was collected on age, sex, hand dominance, type of tumor, and the involved hemisphere. A chi-square test of independence was used to analyze the relationship between hand dominance and tumor grade. P-values less than 0.05 were considered statistically significant. ResultsIn total, 1113 patients with brain tumor with mean age of 41.89 ± 18.06 years, including 708 males (63.6%), were studied in Tehran, Iran. The most common brain tumors were glioblastoma with a frequency of 330 (29.6%) and astrocytoma 183 (16.4%). The rarest tumor types are ependymoblastoma with a frequency of 14 (1.3%). Overall, 551 (49.5%) patients had left hemisphere and 459 (41.2%) had right hemisphere involvement. There was no significant relationship between hand dominance and tumor grade (p>0.05). ConclusionBrain tumors are more common in the fourth and fifth decades of life, and glioblastoma and astrocytoma tumors are the most common brain tumors. The sex distribution of these patients in the present study shows a higher prevalence in men. There was a significant relationship between the hand dominance in patients and contralateral hemisphere involvement.

show abstract

Section: Introductionmentioning

confidence: 99%

Prevalence of primary central nervous system tumors in Iran: a retrospective study

Amini Harandi,

Zarifi,

Shahmohammadi

2023

Univ Med

View full text Add to dashboard Cite

show abstract

“…Previous studies have reported epidemiological characteristics of CNS cancers in Iran and the Middle East and North Africa (MENA) region. However, lack of subnational or national focus on Iran, 2 , 13 , 14 absence of rigorous data sources, and being relatively outdated for the present time 15 , 16 prompt the need for up‐to‐date studies in this regard.…”

Section: Introductionmentioning

confidence: 99%

National and subnational burden of brain and central nervous system cancers in Iran, 1990–2019: Results from the global burden of disease study 2019

et al. 2023

View full text Add to dashboard Cite

Introduction Central nervous system cancers (CNS cancers) impose a significant burden upon healthcare systems worldwide. Currently, the lack of a comprehensive study to assess various epidemiological indexes of CNS cancers on national and subnational scales in Iran can hamper healthcare planning and resource allocation in this regard. This study aims to fill this gap by providing estimates of CNS cancer epidemiological measures on national and subnational levels in Iran from 1990 to 2019. Materials and Methods This study is a part of Global Burden of Disease (GBD) 2019 that contains epidemiological measures including prevalence, incidence, mortality, Disability‐Adjusted Life Years (DALYs), Years Lived with Disability (YLDs), and Years of Life Lost (YLLs) of CNS cancers. Age standardization was utilized for comparing different provinces. Results In 2019, 5811 (95% Uncertainty Interval: 2942–7046) national new cases and 3494 (1751–4173) deaths due to CNS cancers were reported. National age‐standardized incidence (ASIR), deaths (ASDR), and DALYs rates were 7.3 (3.7–8.8), 4.6 (2.3–5.5), and 156.4 (82.0–187.0) per 100,000 in 2019, respectively. Subnational results revealed that ASDR and ASIR have increased in the past 30 years in all provinces. Although incidence rates have increased in all age groups and genders since 1990, death rates have remained the same for most age groups and genders except for young patients aged under 15, where a decrease in mortality and YLLs can be observed. Conclusion The incidence, deaths, and DALYs of CNS cancers increased at national and subnational levels. These findings should be considered for planning and resource allocation.

show abstract

Alterations in hypothalamic-pituitary axis (HPA) hormones 6 months after cranial radiotherapy in adult patients with primary brain tumors outside the HPA region

Shahriari,

Etemadrezaie,

Zabihyan

et al. 2024

Mol Biol Rep

View full text Add to dashboard Cite

Preliminary study of central nervous system tumors’ prevalence and incidence in Isfahan Province Iran

Cited by 5 publications

References 21 publications

Prevalence of primary central nervous system tumors in Iran: a retrospective study

Prevalence of primary central nervous system tumors in Iran: a retrospective study

National and subnational burden of brain and central nervous system cancers in Iran, 1990–2019: Results from the global burden of disease study 2019

Alterations in hypothalamic-pituitary axis (HPA) hormones 6 months after cranial radiotherapy in adult patients with primary brain tumors outside the HPA region

Contact Info

Product

Resources

About